- Home
- KLRS vs IPSC Comparison
KLRS vs IPSC Comparison
Compare KLRS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- IPSC
- Stock Information
- Founded
- KLRS 2019
- IPSC 2019
- Country
- KLRS United States
- IPSC United States
- Employees
- KLRS N/A
- IPSC N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- KLRS Health Care
- IPSC Health Care
- Exchange
- KLRS Nasdaq
- IPSC Nasdaq
- Market Cap
- KLRS 46.0M
- IPSC 45.4M
- IPO Year
- KLRS N/A
- IPSC 2021
- Fundamental
- Price
- KLRS $6.31
- IPSC $0.55
- Analyst Decision
- KLRS Strong Buy
- IPSC Strong Buy
- Analyst Count
- KLRS 3
- IPSC 6
- Target Price
- KLRS $21.50
- IPSC $3.00
- AVG Volume (30 Days)
- KLRS 147.9K
- IPSC 1.5M
- Earning Date
- KLRS 11-12-2025
- IPSC 11-13-2025
- Dividend Yield
- KLRS N/A
- IPSC N/A
- EPS Growth
- KLRS N/A
- IPSC N/A
- EPS
- KLRS N/A
- IPSC N/A
- Revenue
- KLRS N/A
- IPSC $113,337,000.00
- Revenue This Year
- KLRS N/A
- IPSC $1,589.94
- Revenue Next Year
- KLRS N/A
- IPSC N/A
- P/E Ratio
- KLRS N/A
- IPSC N/A
- Revenue Growth
- KLRS N/A
- IPSC 4122.69
- 52 Week Low
- KLRS $2.14
- IPSC $0.34
- 52 Week High
- KLRS $12.90
- IPSC $1.83
- Technical
- Relative Strength Index (RSI)
- KLRS 57.79
- IPSC 52.98
- Support Level
- KLRS $6.04
- IPSC $0.46
- Resistance Level
- KLRS $7.07
- IPSC $0.56
- Average True Range (ATR)
- KLRS 0.66
- IPSC 0.04
- MACD
- KLRS 0.08
- IPSC 0.00
- Stochastic Oscillator
- KLRS 64.94
- IPSC 76.21
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.